Harrison Dillon

Dr. Harrison Dillon is a pioneer and thought leader in industrial biotechnology. He has spent his career at the forefront of emerging biotechnology trends, first as a researcher during the height of the human genome project, then as a patent attorney, and primarily as an entrepreneur. His experience as an entrepreneur has spanned all phases, from garage startup through IPO and beyond, and many roles, from executive to in-house counsel to bench scientist. He is an inventor on over 50 patents and patent applications and has authored articles in scientific, business, and legal journals.

Prior to Phylagen, Dr. Dillon co-founded Solazyme (NASDAQ:SZYM). He served as Chief Executive Officer, Chief Technology Officer and President from 2003 to 2013. Dr. Dillon was also an associate at the law firm Townsend and Townsend and Crew, and managed the biotechnology patent portfolio of the University of Utah in the University’s Technology Transfer Office.

Dr. Dillon received a Ph.D. in Genetics from University of Utah, a J.D. from Duke University School of Law, and a B.S. in Biology from Emory University.